IKT vs LVS · $215.2M cap vs P/E 28, rev $6.74B
Inhibikase Therapeutics Inc (IKT) versus Las Vegas Sands Corp (LVS) — a side-by-side from cached financials, not a winner call.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Las Vegas Sands Corp (LVS) is a resorts & casinos company listed on US.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
Latest reported LVS revenue for 2026-06-30 was $6.74B. Net income was $913.0M. Revenue was up 88.0% from 2026-03-31 to 2026-06-30. LVS currently screens at market cap $35.70B and trailing P/E 28.3.
IKT currently screens at market cap $215.2M. LVS currently screens at market cap $35.70B and trailing P/E 28.3.
Not investment advice. Open the IKT and LVS stock pages for the full models.
Not investment advice.